A prospective observational study on the effect of Erythropoiesis stimulating agents in chronic kidney disease Anemia patients
Keywords:Anemia, Blood transfusion, Erythropoietin, Chronic Kidney Disease, Erythropoiesis Stimulating Agents
Background and Objectives: Anemia is a frequent complication, and significant morbidity and mortality in patient with chronic kidney disease (CKD). Erythropoiesis Stimulating Agents (ESAs) have become the standard care for anemia t erapy and reduces need for blood transfusions. The bjective of the study was to evaluate the safety and effect of ESAs and to create the awareness among patients regarding the Erythropoiesis stimulating agents through patient i formation leaflets.
Methods: The prospective observational study of 6-month duration was conducted in a tertiary care hospital. A total of 162 patients on ESAs were enrolled in the study. Patients were followed for continuously and the mean difference is assessed by monitoring the primary and secondary hematological parameters before and after ESAs administration. Patient information leaflet was given t the patients for education and awareness about ESAs.
Results: Out of 162 patients, after the administration of ESAs mean value increase in hemoglobin level was found from base line 6.9g/dL to 11.6g/dL. Significant improvement was noted in CKD anemia patient indicating impact of patient counseli g.
Conclusion: It can be concluded that Erythropoiesis Stimulating Agents in treatment of anemia along with effective counseling from clinical pharmacist benefits CKD patients and improves the health outcomes.
Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, Gaccione P, Issacs
R. Epidemiology and risk factors of chronic kidney disease in India–results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC nephrology. 2013, Vol 14(1), 114.
Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient preference and adherence, 2008, Vol 2, 195.
Tonelli M, Riella M. Chronic kidney disease and the aging population. Indian J Nephrol, 2014, Vol 24(2), 71–74.
Goldberg I, Krause I. The role of gender in chronic kidney disease. EMJ. 2016, Vol 1(2), 58-64.
Van der Meer V, Wielders HP, Grootendorst DC, de Kanter JS, Sijpkens YW, Assendelft WJ, Gussekloo J, Dekker FW, Groeneveld Y. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. Br J Gen Pract. 2010, Vol 60(581),884-90.
Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Primary care: Clinics in office practice. 2008, Vol 35(2), 329-344.
McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Current medical research and opinion, 2004, Vol 20(9), 1501-1510.
Agarwal SK. Chronic kidney disease and its prevention in India. Kidney int. 2005, Vol 68, S41-45.
Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney international supplements. 2013, Vol 3(4), 368-371.
Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clinical Journal of theAmerican Society of Nephrology, 2009, Vol 4(2),470-480.
Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopathic Medicine and Primary Care.2007,Vol1(1),14.
How to Cite
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.